Research from the STEP trials (semaglutide) and SURMOUNT-4 (tirzepatide) shows that without ongoing pharmacotherapy or substantial behavioral interventions, significant weight regain occurs within the first year after stopping treatment
But even $149 a month, the advertised price for a starting dose of a still-in-development GLP-1 pill on TrumpRx, will be too big a burden for the many Americans struggling to afford groceries. For now, its too early to tell whether this deal will actually change peoples lives or whether the balance of benefits will ultimately favor Big Pharma or patients and taxpayers
Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan
Other notable adverse effects include: Injection site reactions such as erythema, pruritus, or swelling Fatigue reported in approximately 5% to 6% of patients Hypoglycemia when used in combination with insulin or sulfonylureas Increased heart rate with modest elevations of 2 to 4 beats per minute (a class effect of incretin therapies with uncertain clinical significance) Serious but rare adverse effects include acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury (typically secondary to dehydration from gastrointestinal symptoms), and hypersensitivity reactions
